What species does this antibody react with, and has it been used in relevant studies?
The Anti-CTGF antibody reacts with mouse, human, sheep, and rat. It has been shown to work in various applications, including immunohistochemistry, as demonstrated in studies such as those by Liu et al. (2019) and Zhao et al. (2022), where it was used to evaluate CTGF expression in different biological contexts.
Can this antibody be used for immunofluorescence, and what findings have been reported using it in this application?
Yes, the Anti-CTGF antibody has been utilized for immunofluorescence. For instance, in the study by Ulanska-Poutanen et al. (2018), it was employed to assess CTGF expression in tissue sections, contributing to the understanding of cellular responses in the central nervous system following injury.
Is there any evidence of this antibody being effective in studies related to cancer research?
Yes, the Anti-CTGF antibody has been referenced in cancer research, particularly in studies involving pancreatic ductal adenocarcinoma. Resovi et al. (2020) highlighted its role in evaluating CTGF expression within the tumor microenvironment, indicating its potential relevance in understanding tumor progression and therapeutic responses.
How has this antibody been utilized in studies involving the TGF-β signaling pathway?
The Anti-CTGF antibody has been used to investigate the role of CTGF in the TGF-β signaling pathway. For example, Chen et al. (2021) reported that CTGF is upregulated in response to TGF-β1, implicating it in the epithelial-mesenchymal transition process in benign prostatic hyperplasia, showcasing its importance in fibrotic and proliferative responses.